UA115989C2 - Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії - Google Patents

Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії

Info

Publication number
UA115989C2
UA115989C2 UAA201500353A UAA201500353A UA115989C2 UA 115989 C2 UA115989 C2 UA 115989C2 UA A201500353 A UAA201500353 A UA A201500353A UA A201500353 A UAA201500353 A UA A201500353A UA 115989 C2 UA115989 C2 UA 115989C2
Authority
UA
Ukraine
Prior art keywords
muscorinic
antagonists
dry powder
long acting
powder inhaler
Prior art date
Application number
UAA201500353A
Other languages
English (en)
Inventor
Уміт Джіфтер
Алі Туркйілмаз
Онур Мутлу
Гайе Рамазаноглу
Original Assignee
Арвен Айлак Санайі Ве Тіджарет А.С.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48699691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA115989(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Арвен Айлак Санайі Ве Тіджарет А.С. filed Critical Арвен Айлак Санайі Ве Тіджарет А.С.
Publication of UA115989C2 publication Critical patent/UA115989C2/uk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system

Abstract

Винахід стосується фармацевтичної композиції для інгаляції, що містить антагоністи мускаринових рецепторів тривалої дії (ТДМА) у формі сухого порошку в суміші з фармацевтично прийнятним носієм, і їх застосування для лікування респіраторного патологічного стану, вибраного з астми, хронічної обструктивної хвороби легенів (ХОХЛ) та інших обструктивних захворювань дихальних шляхів.
UAA201500353A 2012-07-05 2013-06-24 Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії UA115989C2 (uk)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
TR201207842 2012-07-05
TR201210438 2012-09-12
TR201300194 2013-01-07
PCT/TR2013/000193 WO2014007768A1 (en) 2012-07-05 2013-06-24 Dry powder inhaler compositions comprising long acting muscorinic antagonists

Publications (1)

Publication Number Publication Date
UA115989C2 true UA115989C2 (uk) 2018-01-25

Family

ID=48699691

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201500353A UA115989C2 (uk) 2012-07-05 2013-06-24 Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії

Country Status (6)

Country Link
US (1) US20150150802A1 (uk)
EP (1) EP2682099B1 (uk)
EA (1) EA036153B1 (uk)
GE (1) GEP201706672B (uk)
UA (1) UA115989C2 (uk)
WO (1) WO2014007768A1 (uk)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
EP3203983A1 (en) * 2014-10-08 2017-08-16 Eratech S.r.l. Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
TR201712424A2 (tr) * 2017-08-21 2019-03-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Kuru toz i̇nhalasyon bi̇leşi̇mleri̇
MX2021014343A (es) * 2019-05-24 2022-01-06 Glenmark Pharmaceutical Ltd Una composicion de polvo inhalable de dosis fijas que comprende glicopirronio, formoterol y propionato de fluticasona.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3345722A1 (de) 1983-12-17 1985-06-27 Boehringer Ingelheim KG, 6507 Ingelheim Inhalator
DE4140689B4 (de) 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
EP1430887A1 (de) 2000-10-12 2004-06-23 Boehringer Ingelheim Pharma GmbH & Co.KG Tiotropium-haltige Inhalationspulver
DE10126924A1 (de) 2001-06-01 2002-12-05 Boehringer Ingelheim Pharma Inhalationskapseln
DE10141376A1 (de) 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Inhalationspulvern
KR20090057477A (ko) 2001-09-14 2009-06-05 글락소 그룹 리미티드 호흡기 질환 치료용 펜에탄올아민 유도체
US8337816B2 (en) 2001-09-17 2012-12-25 Glaxo Group Limited Dry powder medicament formulations
DE10212264A1 (de) 2002-03-20 2003-10-02 Boehringer Ingelheim Pharma Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
GB0219513D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions including coarse carrier
US20090298742A1 (en) * 2006-08-09 2009-12-03 Glaxo Group Limited Process for manufacturing lactose
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
EP1944018A1 (en) * 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation
AU2008218962B2 (en) 2007-02-23 2013-03-14 Theravance Biopharma R&D Ip, Llc Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists
ES2425592T3 (es) 2007-04-24 2013-10-16 Theravance, Inc. Compuestos de amonio cuaternario de utilidad como antagonistas de los receptores muscarínicos
PT2197841E (pt) 2007-09-07 2012-01-02 Theravance Inc Compostos contendo guanidina úteis como antagonistas do receptor muscarínico
EP2440196A4 (en) * 2009-06-09 2013-01-02 Elevation Pharmaceuticals Inc TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY ADMINISTRATION OF BETA 2 NEBULIZED AGONIST OR A COMBINATION OF BETA 2 NEBULIZED AGONIST AND ANTICHOLINERGIC
GB0918450D0 (en) * 2009-10-21 2009-12-09 Innovata Ltd Composition
WO2011093813A1 (en) 2010-01-28 2011-08-04 Mahmut Bilgic Dry powder pharmaceutical composition comprising tiotropium and fluticasone
TR201000623A2 (tr) * 2010-01-28 2011-08-22 B�Lg�� Mahmut Yeni tiotropyum kombinasyonu.
WO2011152804A2 (en) 2010-06-03 2011-12-08 Mahmut Bilgic Process for dry powder formulations
WO2011160920A1 (en) 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising an antimuscarinic drug
PT3470057T (pt) * 2010-09-29 2021-12-03 Pulmatrix Operating Co Inc Pós secos catiónicos compreendendo sais de magnésio

Also Published As

Publication number Publication date
EA201590036A1 (ru) 2015-09-30
WO2014007768A1 (en) 2014-01-09
EP2682099A1 (en) 2014-01-08
EP2682099B1 (en) 2020-09-02
EA036153B1 (ru) 2020-10-06
US20150150802A1 (en) 2015-06-04
GEP201706672B (en) 2017-05-25

Similar Documents

Publication Publication Date Title
CY1120605T1 (el) Παρασκευασμα ξηρης σκονης που περιλαμβανει εναν αναστολεα φωσφοδιεστερασης
WO2012110770A3 (en) Combination of glycopyrrolate and a beta2 -agonist
WO2013021199A3 (en) Eutectic mixture for pulmonary administration
EP2682108A3 (en) Dry Powder Inhalers Comprising a Carrier Other Than Lactose and a Ternary Component
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
PH12017502087B1 (en) Tiotropium inhalation solution for nebulization
UA101652C2 (uk) Композиція для інгаляції, що містить аклідиній для лікування астми та хронічного обструктивного захворювання легень
PH12014502662A1 (en) Novel dosage form and formulation of abediterol
EP2682097A3 (en) Dry Powder Inhalers Comprising A Carrier Other Than Lactose
WO2014007770A3 (en) Inhalation compositions comprising corticosteroid and sorbitol
EA201201395A1 (ru) Кнопочное устройство мундштука ингалятора сухого порошка
WO2014007781A3 (en) Inhalation compositions
EA201201397A1 (ru) Ингалятор, содержащий расслаиваемую блистерную упаковку
EA201201391A1 (ru) Ингалятор
UA115989C2 (uk) Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії
WO2014007771A3 (en) Inhalation compositions comprising muscarinic receptor antagonist
EA201201392A1 (ru) Кнопочное устройство мундштука ингалятора сухого порошка
EA201201393A1 (ru) Ингалятор, разработанный для доставки лекарственного средства в виде сухого порошка
EA201201389A1 (ru) Ингалятор, создающий турбулентность
MX2016001539A (es) Particulas inhalables que comprenden tiotropio e indacaterol.
EA201201394A1 (ru) Ингалятор для доставки лекарственного средства в виде сухого порошка
WO2019098969A3 (en) Dry powder compositions for inhalation
BR112015004810A2 (pt) preparações de tiotrópio
TR200909788A2 (tr) Tiotropyum içeren inhalasyona uygun kuru toz formülasyonu
MY191295A (en) Pharmaceutical composition containing budesonide and formoterol